Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calderasib PK Interaction with Itraconazole and Phenytoin
NCT06719557Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of calderasib in solid tumor (2 arms), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Infinity at 72 hours. Started May 2024; status: completed.
02
Drugs
calderasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06719557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719557.